The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1242-1248, December 2005

Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor

From the Department of Internal and Specialistic Medicine, Section of Respiratory Diseases, University of Catania

Received 1 July 2005; received in revised form 8 September 2005; accepted 12 September 2005. published online 14 November 2005.

Catania, Italy

Background

The identification of factors mediating the transition of lung fibroblasts into myofibroblasts is considered fundamental in the comprehension of abnormal reparative processes. Bradykinin, a mediator known for its proinflammatory action, is able to induce cytokine production and contractility in fibroblast cultures.

Objectives

In this study the ability of bradykinin to drive fibroblast into a myofibroblast phenotype at the cellular and molecular level was evaluated.

Methods

α-Smooth muscle actin (α-SMA) expression and TGF-β in bradykinin stimulated fibroblasts were tested by means of flow cytometry, Western blot, and RT-PCR. Cell proliferation and collagen production were evaluated by the colorimetric methylthiazol tetrazolium assay and sirius red assay, respectively. Which bradykinin receptor mediates the expression of α-SMA was evaluated using selective B1 and B2 blocking agents. Furthermore, the effect of bradykinin on extracellular signal-regulated kinase 1/2 phosphorylation was explored.

Results

Bradykinin caused in lung fibroblasts a significant increase in α-SMA at the cellular and molecular level. The B2 receptor was held responsible for this effect because a specific receptor antagonist had entirely blocked this effect. Bradykinin was able to induce fibroblast proliferation and collagen production. Bradykinin significantly activated mitogen-activated protein kinase pathway by phosphorylating extracellular signal-regulated kinase 1/2, whereas PD98059, a specific inhibitor, was able to block myofibroblast induction. Although bradykinin induced an increase of TGF-β on fibroblasts, the blockage of this cytokine did not alter α-SMA expression.

Conclusion

The data support the hypothesis that bradykinin may be involved in bronchial remodeling and lung fibrosis beyond its well recognized proinflammatory activity, also suggesting a new potential therapeutic strategy to control altered reparatory processes.

Key words: Remodeling, lung fibrosis, α-SMA, MAPK

Abbreviations used: α-SMA, α-Smooth muscle actin, ERK, Extracellular signal-regulated kinase, MAPK, Mitogen-activated protein kinase, MFI, Mean fluorescence intensity, MTT, Colorimetric methylthiazol tetrazolium assay

 

 Supported by an Italian Ministry of Instruction, University and Research grant (COFIN ′03 project grant: 2003062507_004).

PII: S0091-6749(05)02111-1

doi:10.1016/j.jaci.2005.09.025

The Journal of Allergy and Clinical Immunology
Volume 116, Issue 6 , Pages 1242-1248, December 2005